Drug notes:
ZM012 Clin0 lymphoma, undisclosed; ZM014 RD lymphoma
About:
Zumutor Biologics is an immuno-oncology company focused on developing antibody-based and immunotherapies for cancer treatment. They aim to target the innate immune system through NK cells and modulate the tumor microenvironment through the development of novel monoclonal antibodies. Zumutor Biologics designs their antibodies utilizing glyco-engineering to increase their efficacy. They are also offering end-to-end antibody library and discovery technology services to other companies to optimize design and speed up development. Their flexible services include both process and analytical development for antibody therapeutics. They also hope to partner for developing bispecific antibodies and CAR-T and CAR-NK therapies using their platform.